Jamal Rana: The LDL Cholesterol Goal Post Has Moved
Jamal Rana, Professor in the Department of Clinical Science at Kaiser Permanente Bernard J. Tyson School of Medicine, shared on LinkedIn:
”Goal post to treat LDL cholesterol has moved in patients with high risk for heart disease. Was thrilled to be part of The Wall Street Journal coverage of the biggest trials presented at AHA Scientific Sessions. We are now in era where multiple options exist to aggressively treat LDL cholesterol in high risk patients to prevent heart disease.
A PCSK9 inhibitor, evolocumab or Repatha, used on top of lipid-lowering therapy, including a high-intensity statin, significantly cuts the risk of major adverse cardiovascular events compared with placebo when used in patients without a prior history of myocardial infarction or stroke, the VESALIUS-CV study shows over a median follow-up of 4.6 years.
A single injection of a gene-edited protein was deemed productive and safe in patients with dyslipidemia that was unresponsive to lipid-lowering therapy, according to a phase I trial. IV CTX310 is an in vivo CRISPR-Cas9 gene-editing drug product targeting ANGPTL3.
CORALreef Lipids trial demonstrated that treatment with enlicitide decanoate, once-daily oral PCSK9-inhibitor, resulted in a statistically significant and clinically meaningful reduction in LDL cholestrol.”
Check here for more information.
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 6, 2026, 16:39Dhinesh Selvaraju: FDA Approves Narsoplimab (Yartemlea) as 1st Treatment for TA-TMA in Adults and Children
-
Apr 6, 2026, 16:38Linda Vorberg: A Detailed Analysis on The Usefulness of CT for DL-Based Stroke Lesion Segmentation
-
Apr 6, 2026, 16:37Colleen Hearn: Telestroke Helps Resource-Limited Facilities Gain Access to Unavailable Expertise
-
Apr 6, 2026, 16:37Nicolas Hubacz: AI Maps Neuroplasticity in Stroke Recovery – How the Brain Adapts After Injury
-
Apr 6, 2026, 16:36Cristina de Diego Alonso: Movement Is Not Just an Exercise, It Is The Rhythm of Daily Life
-
Apr 6, 2026, 16:35Charles Okyere Boadu: What Is The Most Likely Cause of Persistent Thrombocytopenia Despite Transfusion?
-
Apr 6, 2026, 16:34Tumor Mutations and VTE Risk – New Insights from a 12,500-Patient Cancer Study – JTH
-
Apr 6, 2026, 16:31Wolfgang Miesbach: New Real-World Data Reveal Ongoing Burden in Moderate-to-Severe Haemophilia A
-
Apr 6, 2026, 16:26Heghine Khachatryan։ Targeting High Risk Antiphospholipid Syndrome in Pregnancy with Hydroxychloroquine